MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic (Nasdaq: HOLX) announced today that it has completed regulatory filings needed to make Panther Trax ® available in a number of countries and regions.

Hologic, Inc. HOLX recently progressed in terms of the international launch of Panther Trax, representing the newest addition to the Panther Scalable Solutions (PSS) portfolio of products. The company ...

Hologic, Inc. HOLX recently announced the receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays for respiratory virus infections. The Panther Fusion respiratory ...

胃肠病原体检测的Hologic Panther Fusion GI检测方法与Verigene EP、BioFire GI的对比研究表明，三者在主要病原体（如沙门氏菌、弯曲杆菌）检测中PPA和NPA均超过95%，但Fusion GI在Yersinia enterocolitica检测中PPA为72.2%，部分假阴性可能与冻存样本核酸降解有关。 在当今医疗诊断 ...

Hologic’s HOLX fully automated, high-throughput Panther platform remains the foundation of its molecular diagnostics business. The Panther Fusion module, a 2016 addition to the base system, provides ...

New Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays deliver tailored, actionable diagnostic results to support fast and informed patient care A variety of complex factors, ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that it is now offering its Panther Fusion ® SARS-CoV-2/Flu A/B/RSV assay and its Novodiag ® RESP-4 molecular ...

Under CEO Stephen MacMillans' watch, Hologic has been able to focus on structural competitive advantages, improve its balance sheet, and judiciously step into complimentary markets, which evens out ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, ...

Shares of Hologic HOLX closed the first trading session of the year at $74.56, which is quite close to the 52-week high of $75.34, reached on Dec. 15, 2025. In the past six months, the company has ...